FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Indomethacin Extended-Release Capsules Recall

Indomethacin Extended-Release Capsules, USP, 75 mg, packaged in a) 60-count bottle (ND…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Sep 4, 2024
Recall ID
D-0643-2024
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Indomethacin Extended-Release Capsules starting Jul 31, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0643-2024 on Sep 4, 2024. Reason: Failed Dissolution Specifications: below specification results. Status: Ongoing.

Why it was recalled

Failed Dissolution Specifications: below specification results

Product description

Indomethacin Extended-Release Capsules, USP, 75 mg, packaged in a) 60-count bottle (NDC 68462-325-60) and b) 90-count bottle (NDC 68462-325-90), Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2 Phase-2, Pharma Zone, SEZ, Pithampur, Dist-Dhar, Madya Pradesh - 454775, India Mfg Llc. No: 25/9/2010, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.

Lot numbers, UPCs & expiration codes

Lot#: 17240105, Exp 12/31/2025

Where it was sold

Nationwide USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0643-2024
Classification
Class II
Status
Ongoing
Recall initiated
Jul 31, 2024
FDA report date
Sep 4, 2024
Quantity
2404 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0643-2024, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
95075
Address
750 Corporate Dr
Code information
Lot#: 17240105, Exp 12/31/2025
Postal code
07430-2009
Report date
Sep 4, 2024
Product type
Drugs
Recall number
D-0643-2024
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
2404 bottles
Reason for recall
Failed Dissolution Specifications: below specification results
Voluntary / mandated
Voluntary: Firm initiated
Product description
Indomethacin Extended-Release Capsules, USP, 75 mg, packaged in a) 60-count bottle (NDC 68462-325-60) and b) 90-count bottle (NDC 68462-325-90), Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2 Phase-2, Pharma Zone, SEZ, Pithampur, Dist-Dhar, Madya Pradesh - 454775, India Mfg Llc. No: 25/9/2010, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.
Distribution pattern
Nationwide USA
Recall initiation date
Jul 31, 2024
Center classification date
Aug 23, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0643-2024, published Sep 4, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls